<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38717025</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>1901</StartPage><EndPage>1912</EndPage><MedlinePgn>1901-1912</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14309/ajg.0000000000002862</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Personalized management strategies are pivotal in addressing irritable bowel syndrome (IBS). This multicenter randomized controlled trial focuses on comparing the efficacy of a microbiome-based artificial intelligence-assisted personalized diet (PD) with a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet (FODMAP) for IBS management.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred twenty-one patients participated, with 70 assigned to the PD group and 51 to the FODMAP diet group. IBS subtypes, demographics, symptom severity (IBS-SSS), anxiety, depression, and quality of life (IBS-QOL) were evaluated. Both interventions spanned 6 weeks. The trial's primary outcome was the within-individual difference in IBS-SSS compared between intervention groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For the primary outcome, there was a change in IBS-SSS of -112.7 for those in the PD group vs -99.9 for those in the FODMAP diet group ( P = 0.29). Significant improvement occurred in IBS-SSS scores ( P &lt; 0.001), frequency ( P &lt; 0.001), abdominal distension ( P &lt; 0.001), and life interference ( P &lt; 0.001) in both groups. In addition, there were significant improvements in anxiety levels and IBS-QOL scores for both groups ( P &lt; 0.001). Importantly, PD was effective in reducing IBS SSS scores across all IBS subtypes IBS-Constipation (IBS-C; P &lt; 0.001), IBS-Diarrhea (IBS-D; P = 0.01), and IBS-Mixed (IBS-M; P &lt; 0.001) while FODMAP diet exhibited comparable improvements in IBS-C ( P = 0.004) and IBS-M ( P &lt; 0.001). PD intervention significantly improved IBS-QOL scores for all subtypes (IBS-C [ P &lt; 0.001], IBS-D [ P &lt; 0.001], and IBS-M [ P = 0.008]) while the FODMAP diet did so for the IBS-C ( P = 0.004) and IBS-D ( P = 0.022). Notably, PD intervention led to significant microbiome diversity shifts ( P &lt; 0.05) and taxa alterations compared with FODMAP diet.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The artificial intelligence-assisted PD emerges as a promising approach for comprehensive IBS management. With its ability to address individual variation, the PD approach demonstrates significant symptom relief, enhanced QOL, and notable diversity shifts in the gut microbiome, making it a valuable strategy in the evolving landscape of IBS care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tunali</LastName><ForeName>Varol</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1799-2539</Identifier><AffiliationInfo><Affiliation>Department of Parasitology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arslan</LastName><ForeName>Naciye &#xc7;i&#x11f;dem</ForeName><Initials>N&#xc7;</Initials><Identifier Source="ORCID">0000-0002-2282-7207</Identifier><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Medipol Bah&#xe7;elievler Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ermi&#x15f;</LastName><ForeName>Beyza Hilal</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Faculty of Nutrition and Dietetics, Adnan Menderes University, Ayd&#x131;n, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dervi&#x15f; Hakim</LastName><ForeName>G&#xf6;zde</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Tepecik Education and Research Hospital, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ndo&#x11f;du</LastName><ForeName>Aycan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hora</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1187-1349</Identifier><AffiliationInfo><Affiliation>Bioinformatics Division, Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalbanto&#x11f;lu</LastName><ForeName>&#xd6;zkan Ufuk</ForeName><Initials>&#xd6;U</Initials><Identifier Source="ORCID">0000-0002-2278-7786</Identifier><AffiliationInfo><Affiliation>Bioinformatics Division, Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05646186</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009005">Monosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C024617">polyol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="Y">Oligosaccharides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="Y">Disaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009005" MajorTopicYN="Y">Monosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="Y">Polymers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050528" MajorTopicYN="N">Diet, Carbohydrate-Restricted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Guarantor of the article:</b> Varol Tunali, MD, PhD. <b>Specific author contributions:</b> V.T., N.C.A.: conceptualization. V.T., B.H.E.: data curation. &#xd6;.U.N., B.H.E., A.G.: formal Analysis. V.T., &#xd6;.U.N.: funding acquisition. V.T., N.C.A., G.D.H., &#xd6;.U.N.: investigation. V.T., N.C.A., &#xd6;.U.N.: methodology. V.T.: project administration. B.H.E., M.H., A.G.: software. &#xd6;.U.N., M.H.: resources. V.T., &#xd6;.U.N., A.G.: supervision. V.T., G.D.H., B.H.E.: validation. V.T., &#xd6;.U.N.: visualization. V.T., B.H.E., &#xd6;.U.N., A.G.: writing&#x2013;original Draft. V.T., &#xd6;.U.N., N.C.A., G.D.H., A.G.: writing&#x2013;review &amp; editing. <b>Financial support:</b> This research received no external funding, but the microbiome analysis was carried out by ENBIOSIS Biotechnology. A. G&#xfc;ndo&#x11f;du and &#xd6;.U. Nalbanto&#x11f;lu are shareholders of ENBIOSIS Biotechnologies. <b>Potential competing interests:</b> Beyza Hilal Ermis and Mehmet Hora are scientists working with ENBIOSIS Biotechnologies. <b>Data transparency statement:</b> Deidentified individual participant data that underlie the reported results will be made available 3 months after publication for 5 years after the publication date at https://data.mendeley.com/. The study protocol is included as a data supplement available with the online version of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38717025</ArticleId><ArticleId IdType="pmc">PMC11365594</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000002862</ArticleId><ArticleId IdType="pii">00000434-202409000-00029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA 2015;313(9):949&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology 2021;160(1):99&#x2013;114.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol 2012;10(7):712&#x2013;21.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014;146(6):1500&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114504</ArticleId><ArticleId IdType="pubmed">24583088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajili&#x107;-Stojanovi&#x107; M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: Causes, consequences, or epiphenomena? Am J Gastroenterol 2015;110(2):278&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317767</ArticleId><ArticleId IdType="pubmed">25623659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016;14(8):e1002533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991899</ArticleId><ArticleId IdType="pubmed">27541692</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014:146.</Citation><ArticleIdList><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Irving PM, Lomer MCE, et al. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014;11(4):256&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445613</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Heidi Maria Staudacher C. Nutritional, microbiological and psychosocial implications of the low FODMAP diet. J Gastroenterol Hepatol 2017;32(Suppl 1):16&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28244658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015;31(1):69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290017</ArticleId><ArticleId IdType="pubmed">25394236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduction Targeted Ther 2022. 7(1):135&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034083</ArticleId><ArticleId IdType="pubmed">35461318</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: A narrative review. Eur J Clin Nutr 2022. 76(4):489&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8477631</ArticleId><ArticleId IdType="pubmed">34584224</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharjee A, Choudhury SP. Artificial intelligence-based personalized nutrition and prediction of irritable bowel syndrome patients. Therap Adv Gastroenterol 2022;15:17562848221145612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9806427</ArticleId><ArticleId IdType="pubmed">36600681</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakan T, Gundogdu A, Alag&#xf6;zl&#xfc; H, et al. Artificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome. Gut Microbes 2022;14(1):2138672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9629088</ArticleId><ArticleId IdType="pubmed">36318623</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslan N&#xc7;, G&#xfc;ndo&#x11f;du A, Tunali V, et al. Efficacy of AI-assisted personalized microbiome modulation by diet in functional constipation: A randomized controlled trial. J Clin Med 2022;11(22):6612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9698233</ArticleId><ArticleId IdType="pubmed">36431088</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasolli E, Asnicar F, Manara S, et al. Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell 2019;176(3):649&#x2013;62.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349461</ArticleId><ArticleId IdType="pubmed">30661755</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMC Med 2010;340(1):c332&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012;6(8):1621&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400413</ArticleId><ArticleId IdType="pubmed">22402401</ArticleId></ArticleIdList></Reference><Reference><Citation>16S Illumina Amplicon protocol: Earthmicrobiome (http://earthmicrobiome.org/protocols-and-standards/16s/). Accessed August 7, 2023.</Citation></Reference><Reference><Citation>Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 2019;37(8):852&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015180</ArticleId><ArticleId IdType="pubmed">31341288</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 2014;30(15):2114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res 2013;41(Database issue):D590&#x2013;D596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531112</ArticleId><ArticleId IdType="pubmed">23193283</ArticleId></ArticleIdList></Reference><Reference><Citation>Scikit-bio (http://scikit-bio.org/). Accessed July 16, 2023.</Citation></Reference><Reference><Citation>Pedregosa Fabianpedregosa F, Michel V, Grisel Oliviergrisel O, et al. Scikit-learn: Machine learning in Python. J Machine Learn Res 2011;12:2825&#x2013;30.</Citation></Reference><Reference><Citation>Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: Fundamental algorithms for scientific computing in Python. Nat Methods 2020;17(3):261&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7056644</ArticleId><ArticleId IdType="pubmed">32015543</ArticleId></ArticleIdList></Reference><Reference><Citation>Beichl I, Sullivan F. The Metropolis algorithm. Comput Sci Eng 2000;2(1):65&#x2013;9.</Citation></Reference><Reference><Citation>Gibson PR, Shepherd SJ. Personal view: Food for thought: Western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005;21(12):1399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: Management of irritable bowel syndrome. Am J Gastroenterol 2021;116(1):17&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto MCdO, Padhye NS, Bertoni AG, et al. Everything in moderation&#x2013;dietary diversity and quality, central obesity and risk of diabetes. PLoS One 2015;10(10):e0141341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627729</ArticleId><ArticleId IdType="pubmed">26517708</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11(2):395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2016;44(7):693&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">27492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci 1998;43(2):400&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67(6):361&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical power analysis for the behavioral sciences (https://www.taylorfrancis.com/books/mono/10.4324/9780203771587/statistical-power-analysis-behavioral-sciences-jacob-cohen) (2013). Accessed July 28, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.4324/9780203771587/statistical-power-analysis-behavioral-sciences-jacob-cohen</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150(6):1393&#x2013;407.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Algera J, Colomier E, Simr&#xe9;n M. The dietary management of patients with irritable bowel syndrome: A narrative review of the existing and emerging evidence. Nutrients 2019;11(9):2162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6770052</ArticleId><ArticleId IdType="pubmed">31505870</ArticleId></ArticleIdList></Reference><Reference><Citation>Rej A, Avery A, Aziz I, et al. Diet and irritable bowel syndrome: An update from a UK consensus meeting. BMC Med 2022;20:287&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9469508</ArticleId><ArticleId IdType="pubmed">36096789</ArticleId></ArticleIdList></Reference><Reference><Citation>Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130(5):1538&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678567</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: A systematic review and meta-analysis. Eur J Nutr 2021;60(6):3505&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354978</ArticleId><ArticleId IdType="pubmed">33585949</ArticleId></ArticleIdList></Reference><Reference><Citation>Irritable bowel syndrome in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2017 Apr. (NICE Clinical Guidelines, No. 61.) Available from:  https://www.ncbi.nlm.nih.gov/books/NBK553734/ </Citation><ArticleIdList><ArticleId IdType="pubmed">32073807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PR, Gibson P. The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: Is it ready for prime time as a first-line therapy? J Gastroenterol Hepatol 2017;32(Suppl 1):32&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28244668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD. Microbiome-based treatment strategies for irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2019;15(3):164&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6495414</ArticleId><ArticleId IdType="pubmed">31061659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J, St&#xf6;rsrud S, Nev&#xe9; BL, et al. Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. Microbiome 2021;9:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004395</ArticleId><ArticleId IdType="pubmed">33771219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bootz-Maoz H, Pearl A, Melzer E, et al. Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome. Cell Rep 2022;41(7):111657.</Citation><ArticleIdList><ArticleId IdType="pubmed">36384106</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015;64(1):93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J, Derrien M, T&#xf6;rnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017;152(1):111&#x2013;23.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27725146</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet SMP, B&#xf6;hn L, St&#xf6;rsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut 2018;67(5):872&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">28416515</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel S, Leclerc M, Martin R, et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio 2015;6(2):e00300-15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4453580</ArticleId><ArticleId IdType="pubmed">25900655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajili&#x107;-Stojanovi&#x107; M, Biagi E, Heilig HGHJ, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141(5):1792&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">21820992</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: Mechanistic insights. Gut 2022;71(5):1020&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995832</ArticleId><ArticleId IdType="pubmed">35105664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho ZY, Lal SK. The human gut microbiome: A potential controller of wellness and disease. Front Microbiol 2018;9:1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102370</ArticleId><ArticleId IdType="pubmed">30154767</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>